[Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
With ordinary procainamide tablets a dosing interval of 3-4 hours must be chosen to achieve therapeutically useful plasma concentrations during the entire interval. The concentrations of procainamide and its N-acetylated metabolite, NAPA, have been studied in the plasma of 10 normal volunteers and 11 patients who were given a new sustained release preparation at 8 hour intervals. Blood samples were taken between two doses on the fourth day of treatment. Procainamide showed levels within the accepted therapeutic range during the entire dosing interval. A dose of 4.5 g per day per 70 kg body-weight is necessary in order to achieve adequate levels. NAPA concentrations did not fluctuate during the dosing interval and mean steady-state concentrations were influenced predominantly by the degree of renal function. Saliva to plasma concentration ratio, measured in four patients, showed huge inter- and intraindividual variability. Therefore, saliva concentrations measurements of procainamide and NAPA are of little clinical use.
D000120:Acecainide / Q000008:administration & dosage* / Q000097:blood; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood; D012463:Saliva / Q000032:analysis; D013223:Statistics as Topic
D003692:Delayed-Action Preparations; D000120:Acecainide; D011342:Procainamide
Plasma- und Speichelkonzentrationen von Procainamid und N-Acetyl-Procainamid nach Procainamid-Retard-Tabletten.